Emergent Biosolutions Guides $720–760M 2026 Revenue with $135–155M EBITDA Forecast
Emergent Biosolutions reported Q4 revenues of $149M with adjusted EBITDA of $11M, while NARCAN sales dipped due to government uncertainty. Full-year 2025 revenue fell to $743M but adjusted EBITDA rose 12% to $205M with 900bps margin expansion and net leverage at 1.9x; 2026 guidance is $720–760M revenue and $135–155M EBITDA.
1. Q4 Performance and NARCAN Impact
In Q4, Emergent Biosolutions generated $149 million in revenue and $11 million of adjusted EBITDA (8% margin), landing at the high end of guidance. Executive management noted NARCAN demand was temporarily softened by prolonged government shutdown effects and market uncertainty, classifying the impact as transient.
2. Full-Year 2025 Financial and Transformation Results
For full-year 2025, total revenue reached $743 million while adjusted EBITDA climbed 12% to $205 million, driven by a 900 basis point gross margin expansion and a 10% reduction in operating expenses. Operating cash flow surged to $171 million, net leverage improved to 1.9x, and the company returned capital via share repurchases, resolved a legacy legal matter, and paid down $110 million of debt plus a $100 million term-loan prepayment.
3. MCM Segment Expansion and International Contracts
The medical countermeasures (MCM) segment saw sustained contract activity with international sales representing 34% of segment revenue and deliveries to over 20 countries. Emergent secured new biodefense agreements, including a CAD 140 million multi-year pact with Canada, leveraging its infrastructure and scale for growth.
4. 2026 Outlook and Guidance
Management set 2026 revenue guidance at $720–760 million and adjusted EBITDA of $135–155 million, noting results will exclude a one-time $60 million international order that boosted 2025. MCM revenue is expected to be flat to slightly down, commercial revenue flat to slightly up, and the company will invest in pipeline programs, bolt-on acquisitions and NARCAN innovation.